The Impact of Transcriptomics on the Fight against Tuberculosis: Focus on Biomarkers, BCG Vaccination, and Immunotherapy
In 1882 Robert Koch identified Mycobacterium tuberculosis as the causative agent of tuberculosis (TB), a disease as ancient as humanity. Although there has been more than 125 years of scientific effort aimed at understanding the disease, serious problems in TB persist that contribute to the estimate...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2011-01-01
|
| Series: | Clinical and Developmental Immunology |
| Online Access: | http://dx.doi.org/10.1155/2011/192630 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832550503810072576 |
|---|---|
| author | Carlos Rodrigo Zárate-Bladés Celio Lopes Silva Geraldo A. Passos |
| author_facet | Carlos Rodrigo Zárate-Bladés Celio Lopes Silva Geraldo A. Passos |
| author_sort | Carlos Rodrigo Zárate-Bladés |
| collection | DOAJ |
| description | In 1882 Robert Koch identified Mycobacterium tuberculosis as the causative agent of tuberculosis (TB), a disease as ancient as humanity. Although there has been more than 125 years of scientific effort aimed at understanding the disease, serious problems in TB persist that contribute to the estimated 1/3 of the world population infected with this pathogen. Nonetheless, during the first decade of the 21st century, there were new advances in the fight against TB. The development of high-throughput technologies is one of the major contributors to this advance, because it allows for a global vision of the biological phenomenon. This paper analyzes how transcriptomics are supporting the translation of basic research into therapies by resolving three key issues in the fight against TB: (a) the discovery of biomarkers, (b) the explanation of the variability of protection conferred by BCG vaccination, and (c) the development of new immunotherapeutic strategies to treat TB. |
| format | Article |
| id | doaj-art-91bcebb51d9e440583036d43cb82e5ca |
| institution | Kabale University |
| issn | 1740-2522 1740-2530 |
| language | English |
| publishDate | 2011-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Clinical and Developmental Immunology |
| spelling | doaj-art-91bcebb51d9e440583036d43cb82e5ca2025-02-03T06:06:35ZengWileyClinical and Developmental Immunology1740-25221740-25302011-01-01201110.1155/2011/192630192630The Impact of Transcriptomics on the Fight against Tuberculosis: Focus on Biomarkers, BCG Vaccination, and ImmunotherapyCarlos Rodrigo Zárate-Bladés0Celio Lopes Silva1Geraldo A. Passos2The Centre for Tuberculosis Research, Department of Biochemistry and Immunology, School of Medicine of Ribeirão Preto, University of São Paulo (USP), Ribeirão Preto SP, BrazilThe Centre for Tuberculosis Research, Department of Biochemistry and Immunology, School of Medicine of Ribeirão Preto, University of São Paulo (USP), Ribeirão Preto SP, BrazilMolecular Immunogenetics Group, Department of Genetics, Faculty of Medicine of Ribeirão Preto, USP, 14040-900 Ribeirão Preto, SP, BrazilIn 1882 Robert Koch identified Mycobacterium tuberculosis as the causative agent of tuberculosis (TB), a disease as ancient as humanity. Although there has been more than 125 years of scientific effort aimed at understanding the disease, serious problems in TB persist that contribute to the estimated 1/3 of the world population infected with this pathogen. Nonetheless, during the first decade of the 21st century, there were new advances in the fight against TB. The development of high-throughput technologies is one of the major contributors to this advance, because it allows for a global vision of the biological phenomenon. This paper analyzes how transcriptomics are supporting the translation of basic research into therapies by resolving three key issues in the fight against TB: (a) the discovery of biomarkers, (b) the explanation of the variability of protection conferred by BCG vaccination, and (c) the development of new immunotherapeutic strategies to treat TB.http://dx.doi.org/10.1155/2011/192630 |
| spellingShingle | Carlos Rodrigo Zárate-Bladés Celio Lopes Silva Geraldo A. Passos The Impact of Transcriptomics on the Fight against Tuberculosis: Focus on Biomarkers, BCG Vaccination, and Immunotherapy Clinical and Developmental Immunology |
| title | The Impact of Transcriptomics on the Fight against Tuberculosis: Focus on Biomarkers, BCG Vaccination, and Immunotherapy |
| title_full | The Impact of Transcriptomics on the Fight against Tuberculosis: Focus on Biomarkers, BCG Vaccination, and Immunotherapy |
| title_fullStr | The Impact of Transcriptomics on the Fight against Tuberculosis: Focus on Biomarkers, BCG Vaccination, and Immunotherapy |
| title_full_unstemmed | The Impact of Transcriptomics on the Fight against Tuberculosis: Focus on Biomarkers, BCG Vaccination, and Immunotherapy |
| title_short | The Impact of Transcriptomics on the Fight against Tuberculosis: Focus on Biomarkers, BCG Vaccination, and Immunotherapy |
| title_sort | impact of transcriptomics on the fight against tuberculosis focus on biomarkers bcg vaccination and immunotherapy |
| url | http://dx.doi.org/10.1155/2011/192630 |
| work_keys_str_mv | AT carlosrodrigozarateblades theimpactoftranscriptomicsonthefightagainsttuberculosisfocusonbiomarkersbcgvaccinationandimmunotherapy AT celiolopessilva theimpactoftranscriptomicsonthefightagainsttuberculosisfocusonbiomarkersbcgvaccinationandimmunotherapy AT geraldoapassos theimpactoftranscriptomicsonthefightagainsttuberculosisfocusonbiomarkersbcgvaccinationandimmunotherapy AT carlosrodrigozarateblades impactoftranscriptomicsonthefightagainsttuberculosisfocusonbiomarkersbcgvaccinationandimmunotherapy AT celiolopessilva impactoftranscriptomicsonthefightagainsttuberculosisfocusonbiomarkersbcgvaccinationandimmunotherapy AT geraldoapassos impactoftranscriptomicsonthefightagainsttuberculosisfocusonbiomarkersbcgvaccinationandimmunotherapy |